| Bioactivity | Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time[1][2][3]. |
| In Vivo | Letolizumab 抑制 CD40L 三聚体和 CHO-CD40L 在人类 B 细胞 (IC50 值分别为 3.6 nM 和 1.3 nM) 或非人类灵长类 B 细胞 (IC50 值分别为 3.8 nM 和 7.3 nM) 中的活力[2]。Letolizumab (2、10 和 20 mg/kg；静脉注射；一周一次持续 10 周) 延长了肾移植后的恒河猴的存活时间[2]。 Animal Model: |
| Name | Letolizumab |
| CAS | 1450981-87-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103. [2]. Kim SC, et al. Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. Am J Transplant. 2017 May;17(5):1182-1192. [3]. Spicer P, et al. Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future. Expert Opin Investig Drugs. 2019 Feb;28(2):99-106. |